N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA

Jennifer Gill, Vinay Prasad

Research output: Contribution to journalShort surveypeer-review

Abstract

Despite both enthusiasm and concern regarding data sharing from clinical trials, few studies have documented the outputs of data sharing. The FDA has a considerable collection of raw data from drugs for their marketing authorization. An examination of data sharing with the FDA provides a snapshot into studies that this may facilitate.

Original languageEnglish (US)
Pages (from-to)395-399
Number of pages5
JournalTrends in Cancer
Volume7
Issue number5
DOIs
StatePublished - May 2021

Keywords

  • FDA
  • data sharing
  • secondary data analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'N of 1 Data Sharing: The Impact of Data Sharing within the Hematology–Oncology Drug Products Division of the US FDA'. Together they form a unique fingerprint.

Cite this